Actively Recruiting
Phase IV Study of Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV to Understand Drug Levels and Safety
Led by International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Updated on 2026-11-03
40
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics of long-acting injectable cabotegravir and rilpivirine CAB LA RPV LA during pregnancy and postpartum in women with HIV who have viral suppression. This Phase IV, multi-site, open-label study aims to understand how these drugs behave in the body when given before or during pregnancy, including their clearance and trough levels in the second and third trimesters and postpartum periods. The study includes two groups of pregnant women those who started the injectable treatment before conception and continue receiving injections every four weeks, and those who switch from standard oral therapy and begin the injectable treatment after conception, also continuing every four weeks. Participants will receive their prescribed injections as part of their routine clinical care outside the study. Participants and their infants will be enrolled for follow-up from study entry through six weeks postpartum. Researchers will collect blood samples every four weeks to measure drug levels and monitor HIV viral load, virologic failure, resistance, and pregnancy outcomes. Safety will be assessed for both mothers and infants, including adverse events and birth outcomes. The study plans to enroll up to 40 women to achieve 30 evaluable participants overall.
CONDITIONS
Brief Title
Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Research Team
L
Lisa Levy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here